ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland ChinaBusiness Wire • 06/10/22
ChromaDex to Present at the Oppenheimer's 22nd Annual Consumer Growth and E-Commerce ConferenceBusiness Wire • 06/07/22
ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South KoreaBusiness Wire • 06/02/22
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland ChinaBusiness Wire • 05/19/22
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®Business Wire • 05/17/22
ChromaDex Corporation (CDXC) CEO Rob Fried on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/13/22
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022Business Wire • 04/29/22
ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/28/22
ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the WorldBusiness Wire • 04/14/22
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product PortfolioBusiness Wire • 04/06/22
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future InnovationsBusiness Wire • 03/16/22
ChromaDex Corporation (CDXC) CEO Rob Fried on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/10/22
ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson's Disease (PD)Business Wire • 03/02/22
ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022Business Wire • 02/22/22
ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide RibosideBusiness Wire • 02/09/22
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other IngredientsBusiness Wire • 01/31/22
ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) SupplementationBusiness Wire • 01/25/22
ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary SupplementsBenzinga • 01/20/22
ChromaDex and Designs for Health Partner for New Product Development on Niagen®Business Wire • 01/20/22